Aurinia Pharmaceuticals Inc.
AUPH•NASDAQ•Healthcare•Biotechnology

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOPeter Greenleaf
Founded1993
IPO DateJanuary 26, 1999
Employees130
CountryCanada
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.auriniapharma.com
Phone250 744 2487
Address
#140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada

Corporate Identifiers

CIK0001600620
CUSIP05156V102
ISINCA05156V1022
EIN98-1231763
SIC2834

Leadership Team & Key Executives

Peter S. Greenleaf M.B.A.
President, Chief Executive Officer and Director
Joseph M. Miller CPA
Chief Financial Officer
Matthew Maxwell Donley M.B.A.
Chief Operations Officer
Stephen P. Robertson
Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Dr. Gregory F. Keenan M.D.
Chief Medical Officer
Andrea Levin Christopher
Executive Director of Corporate Communications and Investor Relations
Dr. Premchandran Ramiya Ph.D.
Senior Vice President of Manufacturing and Supply Chain